secwatch.observer — SEC 8-K summary
======================================

Issuer:     RECURSION PHARMACEUTICALS, INC. (RXRX)
CIK:        0001601830
Form:       8-K
Filed at:   2025-06-10T23:59:59+00:00
Accession:  0001193125-25-138138
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.05, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Recursion cuts workforce ~20%, extends cash runway to Q4 2027; $11M severance charges
--------------------------------------------------------------------------------

- Workforce reduction of ~20%; expects ~$11M in severance and related costs in 2025.
- Cash runway now projected into Q4 2027; cash burn guidance <$450M in 2025, <$390M in 2026.
- Expects Q2 2025 cash above $500M; includes $28M R&D tax credit and >$100M potential milestone inflows by end 2026.
- Reduction part of streamlined operating strategy and post-integration transitions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1601830/000119312525138138/0001193125-25-138138-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1601830/000119312525138138/d80288d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-138138

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer